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Introduction: In cancer patients, coadministration of methotrexate 
(MTX) and proton pump inhibitors (PPIs) can cause a pharmacoki-
netic interaction for delayed elimination and a subsequent increase 
in blood MTX concentration. Human organic anion transporters 
hOAT1 (SLC22A6) and hOAT3 (SLC22A8) are responsible for renal 
tubular secretion of MTX. We hypothesized that they are involved 
in drug interaction of MTX with PPIs. The aim of this study was to 
evaluate the inhibitory potencies of PPIs on HEK-hOAT1 and HEK-
hOAT3 attempt to give an explanation to this possible drug–drug 
interaction between MTX and PPIs.
Patients (or Materials) and Methods: Uptake experiments were 
performed using HEK Flp-In 293, stably expressing human 
OAT1(SLC22A6) or OAT3 (SLC22A8), by using the Flp-In™ System 
recombinase (Invitrogen®). We analyzed whether the inhibitory 
potencies of omeprazole, lansoprazole, and pantoprazole on OAT-
mediated [3H] MTX uptake in vitro.
Results: MTX shown to be a high-affinity substrate for hOAT3 but 
not for hOAT1 ( hOAT3 Km = 21.17 [5.65] µM). All PPIs showed 
in vitro inhibition of hOAT transporters. For that purpose, PAH, and 
ES were selected for probing hOAT1 and hOAT3 activities. However, 
their IC50 values concerning hOAT1 were 10 to 30 times higher 
than the unbound plasma concentrations of the PPIs. Conducted in 
parallel [3H]MTX uptake into HEK hOAT3 cells was inhibited by all 
PPIs in a concentration-dependent manner omeprazole, lansoprazole, 
and pantoprazole inhibit hOAT3, their IC50 were in the range of the 
therapeutic levels of the IPPs (0.91–8.06 µM).
Conclusion: PPIs significantly affect transport of MTX mediated by 
hOAT3, but this interaction cannot be explained by the inhibitory 
effects of PPIs on renal hOAT1. These in vitro results demonstrate 
that alterations of uptake transporters of MTX function by IPPs 
drugs have to be considered as potential mechanisms underlying 
drug–drug interactions between MTX-IPPs.
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Introduction: Cytochrome P450 3A (CYP3A) is the major enzyme 
metabolizing drugs and xenobiotics in humans. The present study 
aimed to quantitate the extent of in vivo inhibition and induction 
effects of ritonavir, ketoconazole, and rifampin on the intestinal and 
hepatic activity of CYP3A in adult healthy Asians.
Patients (or Materials) and Methods: Fifteen healthy male or female 
Asian adults completed this open-label, single-center, sequential, par-
tial crossover study. Subjects underwent 4 periods of treatments: 
baseline (reference) period; period 1, either ketoconazole 200 mg or 
ritonavir 100 mg twice daily given for 3 days; period 2, either ritona-
vir or ketoconazole given for 3 days (periods 1 and 2 in a randomized 
crossover design); period 3, rifampin 600 mg given nightly for 2 
weeks. At the end of each period, each subject was administered with 
a single intravenous (IV) midazolam 0.75 mg, given in the fasting 
state, and a single oral 1.5-mg dose of midazolam 4 hours later. Serial 
blood samples were taken from the subjects at predose and at various 
time points for up to 12 hours after IV administration of midazolam. 
Concentrations of midazolam were measured using a validated LC/
MS-MS approach. The hepatic midazolam clearance after IV dosing 
was directly modeled in NONMEM and was estimated separately 
for the reference and the test periods. The intestinal midazolam avail-
ability was calculated by dividing oral midazolam availability with 
hepatic midazolam availability. Formal interaction was excluded if 
the 90% CI for the ritonavir, ketoconazole, or rifampin over reference 
ratios for phenotyping metrics (hepatic midazolam clearance and 
intestinal midazolam availability) was within a 0.80 to 1.25 range.
Results: Ritonavir reduced hepatic and intestinal CYP3A activity to 
0.68-fold (90% CI, 0.61–0.73) and to 0.36-fold (0.28–0.52), respec-
tively. Ketoconazole reduced hepatic and intestinal CYP3A activity 
to 0.75-fold (90% CI, 0.69–0.81) and 0.52-fold (0.39–0.83), respec-
tively. Rifampin increased hepatic and intestinal CYP3A activity by 
1.22-fold (90% CI, 1.02–1.42) and 1.41-fold (1.04–2.19), respec-
tively. There was a statistically significant and clinically relevant 
inhibition of the intestinal CYP3A activity due to chronic treatment 
with ritonavir.
Conclusion: Ritonavir treatment resulted in a clinically significant 
reduction in the net intestinal CYP3A activity. Extent of CYP3A 
inhibition produced by ketoconazole was smaller relative to ritonavir, 
especially at the intestinal level.
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Introduction: Estimation of prescription of warfarin (W) taking into 
account its interaction with other medicines in patients with coronary 
heart disease in clinical conditions.
Patients (or Materials) and Methods: The design of the research is 
retrospective. To estimate the level of polypharmacy and to analyze 
the interaction of W with other medicines medical documents of 
61 patients with coronary heart disease have been analyzed. The 
effects of interaction of medicines were estimated according to BNF 
(British National Formulary) in March 2013. Estimation of the level 
of polypharmacy was considered according to the following 3 groups: 
1, those who received 1 to 5 medicines. This shows rational use of 
medicines. 2, those who received 6 to 10 medicines; 3, those who 
received 11 to 15 medicines. The most clinically significant combina-
tions of medicines have been analyzed.
Results: It has been established that in total 61 patients received 
709 medicines. The medicine load for 1 patient was 11.6 medicines; 
77% of the patients received from 11 to 15 medicines, 23% of the 
patients received from 6 to 10 medicines. The research did not reveal 
any patients who received ≤5 medicines. The results testified to a high 
level of polypharmacy. The next stage is the study of combinations of 
W and medicines presenting significant risk in terms of clinical safety. 
W was given in combination with the following medicines: heparin 
– 16% of patients; acetylsalicylic acid (AS acid) – 28% of patients; 
omeprazole – 21%; diclofenac – 13%; ciprofloxacin – 11%; metro-
nidazole – 5%. It has been proved that the combinations of W and 
heparin, AS acid, and omeprazole are inadmissible, because they are 
life-threatening due to hemorrhage complications. Other unfavorable 
combinations of W have been revealed. They are: W + AS acid + 
omeprazole – 10% of patients; W + AS acid + ciprofloxacin – 4%; 
W + AS acid + diclofenac – 14%. These combinations significantly 
increase the risk of gastrointestinal bleeding.
Conclusion: The real clinical practice in hospitals revealed irra-
tional prescription of medicines. The research has registered a high 
level of polypharmacy and dangerous combinations of W with 
other medicines. It has been proved that before prescribing treat-
ment with W it is necessary to consider pharmacology genetics 
options, which are widely used worldwide. This kind of research 
has not been done in Kyrgyzstan. This determines the importance 
of personalized approach to pharmacologic therapy of W. This 
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e76 volume 35 number 8s
work is the first stage for determining the design of pharmacology 
genetics research.
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Introduction: Oxycodone undergoes a relatively complicated metab-
olism producing 3 main metabolites: noroxycodone, oxymorphone, 
and noroxymorphone. Among these metabolites, oxymorphone is 
highly related to the pharmacodynamic effect of oxycodone. It is 14 
times more potent than the parent compound, and its affinity for the 
µ opioid receptor is 3 times higher than morphine. Development of a 
whole-body physiologically based pharmacokinetic (PK) model is an 
approach to predict in vivo metabolism of oxycodone and PK profile 
of each metabolite in different drug–drug interaction (DDI) scenarios.
Patients (or Materials) and Methods: The Simcyp simulator was used 
as a platform and database for simulation of oxycodone’s metabolism 
in virtual healthy populations. Prior in vitro and in vivo data were 
combined to build an oxycodone model which was used to predict 
the PK profile in healthy volunteers. The incorporated parameters 
were optimized by a top-down approach based on the clinical trial 
conducted by Samer et al, where PK profile of 0.2 mg/kg single dose 
oxycodone and its 3 metabolites were monitored in 10 healthy male 
volunteers (n = 10) previously genotyped for CYP2D6 in 4 scenar-
ios (oxycodone administered alone or coadministered with CYP3A 
inhibitor ketoconazole (400 mg) and/or CYP 2D6 inhibitor quinidine 
(100 mg)) (Samer C, Daali Y et al. 2010). The PK data obtained in 
3 interaction scenarios of the latter clinical trial were used to test 
the built model. Simulated trials permitted to evaluate the impact of 
CYP3A and CYP2D6 inhibitions on the concentration–time profiles 
of oxycodone and 3 main metabolites. The simulated studies designs 
were closely matched with the clinical trial and the virtual popula-
tions (1 trial of 10 volunteers, and 10 trials of 10 volunteers) were set 
with the same proportion of each CYP2D6 phenotype as the clinical 
trial (7 extensive, 1 poor and 2 ultrarapid metabolisers).
Results: Pharmacokinetic profiles of oxycodone and 2 predominant 
metabolites (oxymorphone and noroxycodone) were closely simu-
lated by the model.
Mean values (SD).
Oxycodone, noroxycodone, and oxymorphone PK profiles were 
also concordant with the clinical study according to CYP2D6 
phenotypic groups. Obtained DDI magnitudes were also in agree-
ment with the clinical data. Noroxymorphone PK profile was less 
accurately predicted by the model.
Conclusion: The Simyp developped model for oxycodone is valuable 
to predict the metabolism of oxycodone and main metabolites, and 
to simulate DDI involving CYP 3A and 2D6.
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Introduction: Oxcarbazepine (OXC) is a drug indicated for the treat-
ment of partial seizures or generalized tonic-clonic seizures in adults 
and children. It undergoes rapid presystemic reduction with forma-
tion of the active metabolite 10-hydroxycarbazepine (MHD), which 
has a chiral center at position 10, with the enantiomers (S)-(+)- and 
R-(-)-MHD with similar antiepileptic effects. OXC and MHD are 
substrates of P-glycoprotein (Pgp), whereas verapamil is an inhibitor 
of Pgp expressed in various tissues, including the brain. This study 
aims to evaluate the influence of verapamil on the pharmacokinetics 
of OXC and MHD enantiomers in healthy volunteers.
Patients (or Materials) and Methods: The study was conducted in 2 
phases and included 12 adult healthy volunteers. In the Phase I, they 
were treated with 300 mg/12 hours OXC during 5 days. On the fifth 
day, after the last dose, serial blood samples were collected up to 12 
hours. In the Phase II, the same healthy volunteers were treated with 
OXC (300 mg/12 hours during 5 days) associated with verapamil (80 
mg/8 hours during 5 days). On the fifth day, after the last OXC dose, 
serial blood samples were collected up to 12 hours. Plasma concentra-
tions of OXC and MHD enantiomers were evaluated by LC-MS/MS 
coupled with a chiral phase Chiralcel® OD-H column. Pharmacokinetic 
analysis was performed using the software WinNonlin and statistical 
tests were conducted with the significance level set at P < 0.05.
Results: The following pharmacokinetic parameters for OXC were 
obtained in Phase I (median): maximum plasma concentration (Cmax) 
of 1.35 mg/mL in 1.0 hour, area under the plasma concentration 
versus time curve (AUC0–12) of 3.98 μ g·h/mL and half-life of 2.45 
hours. The kinetic disposition of MHD was enantioselective, with 
observation of a higher proportion for the enantiomer S-(+)-MHD 
compared with R-(-)-MHD (AUC0-12S-(+) / R-(-) of 4.10). Verapamil 
treatment (Phase II) decreased the mean residence time (3.83 vs 4.71 
hours) and the apparent volume of distribution (Vdárea /f’)(2.86 vs 
3.78 L/kg) of OXC. Concerning MHD enantiomers, the verapamil 
treatment increased Cmax, AUC and Css for both enantiomers.
Conclusion: Verapamil treatment reduced OXC Vdárea/f’ and 
increased AUC of both MHD enantiomers probably due to the Pgp 
inhibition.
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AUC24h (ng·min/mL) Cmax (ng/mL)
Observed Simulated Simulated Observed Simulated Simulated
n = 10 n = 10 n = 100 n = 10 n = 10 n = 100
Oxycodone 12,086 
(3184)
12,305 
(8002)
12,953 
(6088)
35.9 
(11.3)
32.2 
(14.8)
35.3 
(13.6)
Noroxycodone 7753 
(2127)
7101 
(4442)
7502 
(4875)
15.5 
(4.3)
14.3 
(6.7)
15.3 
(9.7)
Oxymorphone 232 
(142)
179 (145) 244 (267) 0.7 (0.4) 0.7 (0.7) 0.8 (0.7)
